NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing
Seiden B, Weng S, Sun N, Gordon D, Harris W, Barnett J, Myrie A, Jones T, Pak S, Fudl A, Shields J, McNeil B, Weiss J, Smith M, Esdaille A, Winer A. NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing. Urology 2021, 163: 81-89. PMID: 34688772, DOI: 10.1016/j.urology.2021.08.055.Peer-Reviewed Original ResearchMeSH KeywordsAgedGenetic TestingHumansMaleNeoplasm GradingProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesRisk AssessmentConceptsNCCN riskIntermediate riskGenomic testingLower riskPre-biopsy prostate specific antigenNational Comprehensive Cancer Network guidelinesIntermediate-risk prostate cancerFavorable intermediate riskNCCN risk classificationPre-biopsy PSARisk classificationRisk prostate cancerUnfavorable intermediate riskProstate-specific antigenInitial risk classificationMedian ageBlack patientsNetwork guidelinesActive surveillanceProstate cancerHigher oddsSpecific antigenNonparametric statistical testingPatientsRisk